Conference Coverage

In Relapsed Ovarian Cancer, Topotecan + Carboplatin Failed to Improve PFS, OS

By

Topotecan plus carboplatin failed to improve progression-free survival (PFS) or overall survival (OS) compared with standard therapy (paclitaxel/carboplatin, gemcitabine/carboplatin, or carboplatin/pegylated doxorubicin) in patients with platinum-sensitive relapsed ovarian cancer, according to results of the randomized phase 3 HECTOR study presented at the 2012 American Society of Clinical Oncology Annual Meeting.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs